News Sentiment

VVOS sentiment intelligence

Vivos Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.43 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -24.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Investor group takes 19.9% position in Vivos Therapeutics (VVOS)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -24.5% over four weeks
Fair value -88.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
TradingView 7
TradingKey 4
MT Newswires 3
Investing.com Canada 2
StockStory 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 15
Balance sheet 7
Deals and strategy 5
Analyst action 2
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Stock Titan Direct company coverage

Investor group takes 19.9% position in Vivos Therapeutics (VVOS)

An investor group, including V-CO Investors LLC and Michael C. Skaff, has reported a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 2,783,102 common shares. This position stems from a $1.6 million subscription by V-Co 4, which included the conversio

Tone
Positive 62/100
Event
Deals and strategy
Published
16 Jul 2026 21:20
Source
Stock Titan
TradingView Direct company coverage

Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake

Michael C. Skaff, through SP Manager LLC and its V-Co investment vehicles, has disclosed a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. This investment, formalized in a Schedule 13D filing, stems from a private placement in June 2026 that included convertible pref

Tone
Positive 61/100
Event
Deals and strategy
Published
15 Jul 2026 21:20
Source
TradingView
Stock Titan Direct company coverage

Vivos Therapeutics (NASDAQ: VVOS) holder discloses warrant and preferred stake

V-Co Investors 4 LLC, a 10% owner of Vivos Therapeutics (NASDAQ: VVOS), has disclosed its initial beneficial ownership of a Common Stock Purchase Warrant and Series A Convertible Preferred Stock. Both securities are convertible into 2,749,330 common shares at an exercise/conversi

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 20:20
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Vivos Therapeutics Inc on July 15. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. The article provides the title and source, indicating it's a routine financial disclosu

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:20
Source
Investing.com Canada
www.timothysykes.com Direct company coverage

Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Vivos Therapeutics Inc. (VVOS), currently trading at $0.4178 with a slight decrease. It notes that there are no current analyst ratings or earnings information available for the company. The page is part of a trading education platfor

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 00:20
Source
www.timothysykes.com
TradingView Direct company coverage

Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS

This article displays financial information for Vivos Therapeutics, Inc. (NASDAQ: VVOS), specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data platform, showing basic company identification and navig

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 23:39
Source
TradingView
TradingView Direct company coverage

Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital

Vivos Therapeutics completed a $2.1 million private placement (PIPE) with V-Co Investors 4 and Bigger Capital Fund, involving Series A Convertible Preferred Stock and warrants. The company received $1.0 million in cash, with another $1.0 million from a converted bridge note. Vivo

Tone
Positive 74/100
Event
Balance sheet
Published
08 Jul 2026 10:39
Source
TradingView
Stock Titan Direct company coverage

Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants

Vivos Therapeutics completed a private PIPE financing on June 30, 2026, raising approximately $2.1 million. The financing involved selling units consisting of Series A Convertible Preferred Stock, five-year warrants at an exercise price of $0.456, and contingent subscription righ

Tone
Positive 62/100
Event
Market update
Published
07 Jul 2026 21:30
Source
Stock Titan
Finviz Direct company coverage

VVOS - Vivos Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for Vivos Therapeutics Inc (VVOS). It includes key financial metrics such as market cap, enterprise value, income, sales, and various ratios. The data also covers stock performance, insider and institutional ownership, and a

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 10:10
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS

The article focuses on the enterprise value to EBITDA forward for Vivos Therapeutics, Inc. (NASDAQ:VVOS). It appears to be a financial data point presented within the TradingView platform for the company's NASDAQ listing.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 04:40
Source
TradingView
Benzinga Direct company coverage

12 Health Care Stocks Moving In Tuesday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Tuesday's after-market trading session. It details both gainers and losers, including Alzamend Neuro, Vivos Therapeutics, Advanced Biomed, Aclaris Therapeutics, NexGel, and Aethlon Medical as gainers

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 07:39
Source
Benzinga
Stock Titan Direct company coverage

Vivos says its Vida appliance improved insomnia in all 37 patients

Vivos Therapeutics announced compelling clinical data for its FDA-cleared Vida® oral appliance, showing statistically significant improvement in insomnia severity in all 37 study participants. The appliance, which reduced Insomnia Severity Index scores by an average of 65%, is al

Tone
Negative 38/100
Event
Market update
Published
30 Jun 2026 20:39
Source
Stock Titan
Market source Direct company coverage

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics announced that its FDA-cleared Vida® oral appliance demonstrated statistically significant improvement in insomnia severity for 100% of participants in a recent clinical study. The study, involving 37 adult patients with moderate to severe insomnia, showed an a

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 13:10
Source
Market source
TradingView Direct company coverage

Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS)

This article provides an overview of Vivos Therapeutics, Inc. (NASDAQ:VVOS) stock performance, financial data, and analyst estimates. Key figures include the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, market capitalizati

Tone
Negative 38/100
Event
Analyst action
Published
26 Jun 2026 00:10
Source
TradingView
Stock Titan Direct company coverage

Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact

Vivos Therapeutics has extended its debt-for-equity agreement with Streeterville Capital, pushing the deadline for a $2.6 million equity financing to August 31, 2026. This extension gives Vivos more time to raise capital, with Streeterville reaffirming its commitment to convert u

Tone
Positive 61/100
Event
Market update
Published
25 Jun 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville

Vivos Therapeutics has entered into a debt-for-equity Exchange Agreement with Streeterville Capital to convert debt into stock, aiming to reduce leverage and improve liquidity. Additionally, the deadline for completing a $2.6 million financing was extended to August 31, 2026, pro

Tone
Neutral 50/100
Event
Balance sheet
Published
25 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

VVOS Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Vivos Therapeutics, Inc. (VVOS) stock, including analyst ratings, historical performance, and financial data. It indicates a significant decrease in stock price over the past year and presents analyst price estimates for the f

Tone
Negative 36/100
Event
Analyst action
Published
25 Jun 2026 16:10
Source
TradingView
Market source Direct company coverage

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics and Streeterville Capital, LLC have extended their strategic financing agreement through August 31, 2026. This extension allows Vivos Therapeutics more time to complete its capital-raising requirements. Streeterville reaffirmed its commitment to convert up to $

Tone
Positive 62/100
Event
Balance sheet
Published
25 Jun 2026 12:40
Source
Market source
Moomoo Direct company coverage

Press Release: Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics and Streeterville Capital have extended the timeframe of their strategic financing agreement. This extension reaffirms their commitment to converting Streeterville's existing debt into Vivos common stock and perpetual preferred equity. The agreement aims to sig

Tone
Positive 63/100
Event
Balance sheet
Published
23 Jun 2026 05:10
Source
Moomoo
Investing.com Direct company coverage

Vivos extends debt conversion deadline with Streeterville to August

Vivos Therapeutics Inc. has extended its debt conversion agreement with Streeterville Capital, LLC until August 31, 2026. This extension allows Vivos more time to raise $2.6 million in equity, after which Streeterville will convert up to $4.5 million in outstanding debt into perp

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jun 2026 12:41
Source
Investing.com
Investing.com Canada Direct company coverage

Vivos extends debt conversion deadline with Streeterville to August By Investing.com

Vivos Therapeutics Inc. has extended its debt conversion deadline with Streeterville Capital, LLC to August 31, 2026. This extension allows Vivos more time to complete a planned equity raise and rights offering, aiming to strengthen its stockholders' equity and maintain Nasdaq li

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jun 2026 12:40
Source
Investing.com Canada
TradingKey Direct company coverage

Vivos Therapeutics Inc (VVOS) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Vivos Therapeutics Inc (VVOS). It presents a table of institutional shareholdings, detailing the number of shares held by various entities like V-CO Investors, L.L.C. and Armistice Capital LLC, and h

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis

Vivos Therapeutics Inc (VVOS) currently holds a valuation score of 9.29, placing it 23rd out of 203 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -0.23, which is significantly below its recent high and above its recent low. However, key val

Tone
Negative 36/100
Event
Market update
Published
19 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividend payouts and stock splits for Vivos Therapeutics Inc (VVOS). It indicates that the company has distributed no dividends over the past five years and details multiple 25-to-1 merger-related stock splits that occurred on October

Tone
Negative 40/100
Event
Deals and strategy
Published
18 Jun 2026 17:09
Source
TradingKey
TradingKey Direct company coverage

Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering its business segments. Key revenue contributors include sleep testing services, appliance sales to integrated providers, and center revenue. The data presented reflects fi

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 16:09
Source
TradingKey